EUCTR2007-003704-35-ES进行中（未招募）1 期
Ensayo Clínico aleatorizado, doble ciego, comparado con placebo, para evaluar la eficacia, seguridad y tolerabilidad de Tenofovir Disoproxil Fumarato en adolescentes infectados por la Hepatitis B crónicaA Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection
Gilead Science Incorporated0 个研究点目标入组 106 人开始时间: 2008年7月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female
- •12 through 17 years of age, inclusive (consent of parent/legal guardian required)
- •Documented chronic HBV infection, defined as positive serum HBsAg = 6 months
- •HBeAg positive
- •Weight = 35 kg
- •Able to swallow oral tablets
- •HBV DNA =10^5 copies/mL (PCR method)
- •ALT = 2 × ULN at screening, OR any history of ALT = 2 × ULN over the past = 24 months
- •Willing and able to provide written informed consent/assent (child and parent/legal guardian)
- •Negative serum ß HCG pregnancy test (for post-menarchal females only)
- •Estimated glomerular filtration rate (creatinine clearance) = 80 mL/min/1.73m2
- •Adequate hematologic function (absolute neutrophil count = 1,500/mm3; hemoglobin = 10.0 g/dL)
- •No prior tenofovir DF therapy (subjects may have received prior interferon or oral anti-HBV nucleoside/nucleotide therapy; subjects must have discontinued interferon therapy = 6 months prior to screening; subjects experienced on anti-HBV nucleoside/nucleotide therapy must have discontinued therapy = 16 weeks prior to screening to avoid flare if randomized to the placebo arm)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study.
- •Sexually-active males and females of reproductive potential who are not willing to use an effective method of contraception during the study. For males, condoms should be used and for females, a barrier contraception method should be used in combination with one other form of contraception.
- •Decompensated liver disease defined as direct (conjugated) bilirubin > 1.2 x ULN, PT > 1.2 x ULN, platelets < 150,000/mm3, serum albumin < 3.5 g/dL, or prior history of clinical hepatic decompensation (e.g., ascites, jaundice, encephalopathy, variceal hemorrhage).
- •Receipt of interferon (pegylated or not) therapy within 6 months of the Screening Visit
- •Receipt of anti-HBV nucleoside/nucleotide therapy within 16 weeks of the Screening Visit
- •a-fetoprotein > 50 ng/mL
- •Evidence of hepatocellular carcinoma (HCC)
- •Co infection with HIV, HCV, or HDV
- •History of significant renal disease (e.g., nephrotic syndrome, renal dysgenesis, polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal disease)
- •History of significant bone disease (e.g., osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochrondroses, multiple bone fractures)
- •Significant cardiovascular, pulmonary or neurological disease
- •Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of orally administered medications
- •History of solid organ or bone marrow transplantation
- •Ongoing therapy with any of the following:
- •- Nephrotoxic agents
- •- Chronic daily non-steroidal anti-inflammatory drug therapy
- •Administration of any of the above medications must be discontinued at least 30 days prior to the Baseline Visit and for the duration of the study period.
- •Known hypersensitivity to the study drugs, the metabolites or formulation excipients
- •Any other condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements
研究者
相似试验
进行中（未招募）
1 期
Ensayo clínico aleatorizado, doble ciego, doble enmascarado, de grupos paralelos con control activo para evaluar la eficacia antiviral de 400mg QD de Nevirpaina liberación prolongada (neVirapine Extended Release) en comparación con 200mg BID de nevirapina liberación inmediata (neVirapinE immediate release) en combinación con Truvada® en pacientes infectados por VIH-1 que no hayan recibido tratamiento antirretroviral previo (naïve) (VERVE)A randomised, double blind, double dummy, parallel group, activecontrolled trial to evaluate the antiviral efficacy of 400 mg QDnevirapine extended release formulation in comparison to 200 mg BIDnevirapine immediate release in combination with Truvada® inantiretroviral therapy naïve HIV-1 infected patientsEUCTR2007-003654-29-ES958
进行中（未招募）
不适用
Ensayo clínico aleatorizado, doble ciego, doble enmascarado, multicéntrico para evaluar la eficacia y seguridad de 5 mg de mifepristona oral comparado con triptorelina IM administrados durante 4 meses en el tratamiento de fibroma uterino - MIFLIT09fibroma uterinoMedDRA version: 9Level: LLTClassification code 10046787Term: Uterine fibromyomaEUCTR2009-017222-39-ESaboratorios Litaphar S.A.
进行中（未招募）
不适用
Ensayo clínico aleatorizado, doble ciego, doble dummy, controlado con placebo, para valorar la eficacia y seguridad de diferentes presentaciones de inmunoterapia subcutánea en pacientes asmáticos sensibilizados a Olea europaea y Lolium perenneAsmaEUCTR2004-004317-42-ESBial Industrial Farmacéutica S.A.
进行中（未招募）
不适用
Ensayo clínico aleatorizado doble ciego frente a placebo para evaluación del tratamiento con colistina inhalada en EPOC y/o bronquiectasias no fibrosis quística con infección bronquial crónica por Pseudomonas aeruginosa.Infección bronquial crónica por Pseudomonas aeruginosa en pacientes con EPOC y/o bronquiectasias no fibrosis quísticaMedDRA version: 9Level: HLGTClassification code 10006436Term: Bronchial disorders (excl neoplasms)EUCTR2008-006144-18-ESComplejo Hospitalario Universitario de Albacete. Director Gerente Dr Jesús Martino Sánchez Martínez
进行中（未招募）
不适用
Ensayo clínico aleatorizado, doble ciego con propionato de fluticasona tópico 2 veces por semana, como tratamiento de mantenimiento, para reducir el riesgo de recidivas de dermatitis atópica leve o moderada en niño.Randomised controlled, double blind trial of topical twice weekly fluticasone propionate maintenance treatment to reduce risk of relapse in mild or moderate atopic dermatitis in children. - Fluticasona tópica en niños con DADermatitis AtópicaMedDRA version: 9.1Level: LLTClassification code 10003639Term: Atopic dermatitisEUCTR2008-005360-14-ESElena Rubio. Consorcio Hospital General Universitario de Valencia